AIC (AICAR): What the Research Actually Shows in 2026

AIC (AICAR): What the Research Actually Shows in 2026

Type "aic" into a search bar and the internet splits three ways. You might want Alice in Chains. You might want American International College scores. Or you might have landed on a gray-market vial of AICAR, a compound sold online as an "exercise pill" and discussed on fitness forums like a proven performance drug.

AICAR has a genuine scientific résumé: Phase 3 human trials, one of the most famous mouse studies in exercise biology, and a 17-year ban from the World Anti-Doping Agency. What it doesn't have is a single published human trial showing it improves endurance, burns fat, or does anything else a gym-goer would care about.

Quick Answer

AICAR (drug name acadesine) is a small molecule—not a peptide—that switches on AMPK, an enzyme your cells use to sense low energy. A 2008 mouse study made it famous as an exercise mimetic, which is why WADA banned it in 2009 and why it circulates online as a workout drug. As of August 2026, it is not FDA-approved for any use, no human performance trial has ever been published, and vials sold online carry "research use only" labels with no purity, dosing, or safety guarantees.

This article is for general education only and does not replace medical advice from a licensed healthcare professional.

How AICAR Works: Faking the Cell's Low-Battery Signal

AICAR is not a peptide. It is a nucleoside analog—a small molecule structurally related to adenosine, a building block your cells use to make RNA and store energy. Its full name is 5-aminoimidazole-4-carboxamide-1-β-D-ribofuranoside; researchers call it acadesine or AICA-riboside.

It's also a prodrug: the compound you administer isn't the one that acts. Inside a cell, AICAR converts into ZMP, a close mimic of AMP—the chemical "low battery" alert that builds up when a cell runs short on energy. ZMP switches on AMPK (AMP-activated protein kinase), the enzyme that reads that alert. AMPK then pushes the cell toward burning glucose and fat and building more mitochondria, the structures that produce energy.

A 2021 review in Cells documented that many AICAR effects once credited to AMPK actually happen through separate pathways—this is a blunt instrument, not a clean switch. And unlike metformin, which activates AMPK by creating real energy stress, AICAR fakes the signal without the deficit. Whether a faked signal delivers the same benefits as the real thing remains an open question.

Tested in Humans, Then Abandoned: The Regulatory Record

AICAR is not FDA-approved for anything—not metabolism, not recovery, not heart protection. And this is not a case of "not yet approved." It was tested in humans and failed.

The largest test was RED-CABG, a Phase 3 trial published in JAMA in 2012: 3,080 heart-surgery patients, stopped early for futility when acadesine matched placebo almost exactly—5.1% versus 5.0% on the main outcome. Earlier leukemia trials showed acceptable safety but went nowhere. The drug program was shelved.

What remains is the gray market: vials labeled "for research use only." That label is a legal disclaimer, not a quality grade, and selling such products for human use is illegal in the US. In July 2026, a federal case against the vendor Paradigm Peptides ended in a nearly six-year prison sentence for exactly that fiction—the same one the wider gray-market peptide trade still runs on.

Athletes face a separate rulebook. WADA has prohibited AICAR since 2009 as a metabolic modulator, in and out of competition, and it remains on the 2026 list, which newly added a second AMPK-pathway compound, BAM15. Regulators are watching this class, not loosening on it.

One Mouse Study Built the Entire Hype

Every endurance claim about AICAR traces to a single 2008 study in Cell00838-6). Sedentary mice given AICAR for four weeks ran 44% farther and 23% longer on a treadmill than untreated mice. In rodents.

Decades of follow-up have not produced one published human performance trial. As of August 2026, not one.

The animal work continues. A 2025 BYU study found AICAR sped muscle repair in mice—and the lead researcher put it bluntly: "AICAR is only potent in mice." A 2025 mouse study on diabetic nerve damage noted that IV doses up to 210 mg/kg were tolerated in the old human trials, with mild, short-lived side effects at similar rates in drug and placebo groups up to 100 mg/kg. That describes short-term IV tolerance in monitored patients decades ago. It says nothing about injecting a powder bought online.

Forums fill that vacuum with anecdotes. But anecdotes cannot separate a compound's effect from training changes, diet, expectation, or whatever else was actually in the vial—the same evidence gap that surrounds BPC-157 and most gray-market compounds.

What to Tell a Doctor if AICAR Is in the Picture

No prescribing information exists for AICAR, so no clinician can reference an established safety profile for self-administered use. Honesty is the most useful thing you can bring to an appointment: what was taken, for how long, from what source, and alongside what else. Gray-market products add unknowns no blood test can decode—purity, sterility, actual dose.

Seek urgent care for chest pain, fainting, confusion, or yellowing of the skin or eyes, whatever you suspect caused them. If you compete in drug-tested sports, tell your doctor and check your federation's rules. A positive test does not care that human efficacy was never proven.

What the Internet Gets Wrong About AICAR

• "It's a research peptide." It is not a peptide at all, and "research use only" is a disclaimer, not a legal loophole. "It almost got approved, so it's basically medicine." It was tested in thousands of humans and abandoned for lack of benefit—the opposite of an endorsement. "It boosts endurance 44%." In sedentary mice, in one study, never replicated in people. "It's basically metformin or Cardarine." Metformin is an approved drug with decades of human data. GW501516 (Cardarine) hits a different target entirely—PPARδ, not AMPK. Similar marketing, unrelated pharmacology.

Bottom Line: Interesting to Scientists, Not Useful to You

AICAR is a real research tool with a dramatic paper trail: big human trials that failed, a famous mouse study that triggered a doping ban, and ongoing animal work whose own authors say it may not translate. Online, that nuance gets compressed into "exercise in a vial." The verified record says otherwise: unapproved, unproven in humans for any fitness purpose, and sourced, when bought online, from a market with no quality floor. Fascinating on a lab bench doesn't mean smart to inject.

AICAR FAQ

Is AICAR a peptide? No. It is a small-molecule nucleoside analog (acadesine), chemically related to adenosine. Research-chemical vendors list it alongside peptides, which is where the confusion starts.

Does AICAR really increase endurance? Only in mice. The 44% figure comes from one 2008 rodent study, and as of August 2026 no human performance trial has ever been published.

Is AICAR FDA-approved or legal to buy? It is approved for nothing. Vendors sell it labeled "for research use only," and marketing it for human consumption is illegal in the US—sellers have gone to prison for it.

What side effects does AICAR have in humans? In decades-old IV trials, doses up to 210 mg/kg were tolerated, with mild, short-lived effects reported at similar rates in placebo groups up to 100 mg/kg. Long-term safety is unknown, and so is the actual content of a gray-market vial.

Why did WADA ban AICAR if it is unproven in humans? WADA bans substances with performance-enhancing potential, not just proven ones. The mouse data plus the AMPK mechanism qualified; AICAR has been prohibited in and out of competition since 2009.

Is AICAR the same as metformin or Cardarine? No—three different stories. Metformin is an approved diabetes drug that activates AMPK indirectly. AICAR mimics the AMP signal directly and is approved for nothing. GW501516 (Cardarine) acts on PPARδ, a different pathway altogether.